Telo Genomics Corp. announced the appointment of Kris Weinberg as Chief Executive Officer ("CEO"), effective December 12, 2022. Telo Genomics' current CEO, Sherif Louis PhD, will assume the position of President &Chief Technology Officer.

Mr. Weinberg is an accomplished industry veteran and commercial leader with deep, hands-on experience in the field of high value molecular testing, with a focus on the commercialization of innovative oncology technologies. Mr. Weinberg most recently led the commercial activities at Theralink Technologies, where he successfully launched the Theralink Assay for Breast Cancer to physicians and payors nationally in the US. Kris previously held commercial leadership roles at Natera, Guardant Health, Biodesix and Genomic Health; where he was successful in launching innovative cancer tests across multiple platforms.